Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose QP-6211 for postoperative analgesia in fracture fixation removal surgery (Phase II)
CTR20251626Phase 2Completed
- Sponsor
- ClearPoint Biotech
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QP-6211 in postoperative pain, sponsored by ClearPoint Biotech. Started Apr 2025; status: completed.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20251626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251626.